Manulife Singapore to offer multi-cancer blood test starting May

This will be rolled out through its Guardant Health partnership.

Manulife Singapore will make available the Shield™ multi-cancer detection (MCD) laboratory developed test in Singapore from May 2026 through its partnership with Guardant Health.

The insurer said it will be the first in Singapore to offer eligible customers access to the test, which screens for multiple cancers using a blood sample.

The initiative builds on an existing arrangement between the two companies that also includes access to Guardant Health’s Guardant360® Liquid test.

The Shield™ MCD test was recognised as Oncology Product Innovation of the Year at the Healthcare Asia Medtech Awards, according to the companies.

Manulife Singapore said the rollout forms part of its focus on longevity and preventive healthcare.

“Our role is to help customers take charge of their health and finances with confidence,” said Benoit Meslet, President and CEO, Manulife Singapore.

Cancer accounted for 26.5% of deaths in Singapore in 2024, according to figures cited by the company, as demand for earlier detection and preventive screening increases in line with an ageing population.

The Shield™ MCD test has received Breakthrough Device Designation from the US Food and Drug Administration, according to Guardant Health.

Manulife Singapore said its broader health partnerships with Guardant Health and AMILI include access to Guardant360® Liquid biopsy testing for advanced solid tumours, which provides genomic profiling using a blood sample with results available within seven days.